Company: PSTV
Filing Date: 2025-05-02
Form Type: 8-K
Source: 0000950170-25-062742
Chunk: 4

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-05-02
Form: 8-K
Item: Item 8.01
Chunk 4
---
Item 8.01 Other Events.

Following the approval of the Issuance Proposal and expiration of a 10-trading-day reset period, the exercise price of the Warrants will be reset to the greater of (i) the lowest single trading day volume weighted average price of the Common Stock during the reset period and (ii) $0.132 (the “ Floor Price”). If the exercise price of the Series A Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,138 outstanding Series A Warrants would become exercisable for an aggregate of up to 280,421,380 shares of Common Stock. In addition to the reset provision, the Series B Warrants are subject to a zero exercise price provision (i. e., “alternative cashless exercise”), pursuant to which the Series B Warrants can be exercised without further payment to us and for three times the number of shares of Common Stock issuable upon exercise of the Series B Warrants for cash. The 28,042,138 outstanding Series B Warrants are exercisable for an aggregate of up to 84,126,414 shares of Common Stock assuming the Series B Warrants are exercised pursuant to the zero exercise price provision. In the event that the exercise price of the Series B Warrants is reduced to the Floor Price pursuant to the reset provision, the Series B Warrants would become exercisable for an aggregate of up to 420,632,070 shares of Common Stock, or an aggregate of up to 1,261,896,210 shares of Common Stock assuming the Series B Warrants are exercised pursuant to the zero exercise price provision.

Item 9.01 Financial Statements and Exhibits.